PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.93%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-33.93%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-34.35%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-34.53%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-34.53%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
57.96%
OCF growth of 57.96% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
57.96%
FCF growth of 57.96% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.43%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-44.43%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-44.43%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-265.20%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 6.96%. Seth Klarman might see a fundamental problem if peers maintain growth.
-265.20%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-265.20%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-54.37%
Negative 10Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-54.37%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 9.46%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-54.37%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 9.46%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.76%
AR growth of 21.76% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
No Data
No Data available this quarter, please select a different quarter.
0.79%
Asset growth of 0.79% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-27.60%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
33.93%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.